{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:23:38Z","timestamp":1790969018144,"version":"4.1.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The treatment landscape for chronic lymphocytic leukemia (CLL) has expanded dramatically over the last decade, with a wide range of effective treatments now available. Clinical management of CLL varies widely depending on patient profile, meaning the optimal treatment in Arab patients, who tend to be young and often present with comorbidities, including diabetes and obesity, requires specific considerations. In the absence of regional guidelines, a group of experts from across the Gulf region and one international expert from Germany convened to discuss and agree upon a position statement for venetoclax-based fixed-duration treatment strategies for Arab patients with CLL. Our position is that ibrutinib-venetoclax should be the first choice as first-line therapy for all fit CLL patients in the region, regardless of age. The advantages of an all-oral, fixed-duration treatment are discussed in the context of a young Arab patient population, including excellent patient and physician convenience, limited accumulative risk of toxicities, uncomplicated logistics, and low burden of healthcare administration costs. Finally, we discuss the management of key safety considerations in Arab populations including ethnic neutropenia, risk of cardiotoxic events, considerations during intermittent fasting, and avoiding adverse drug\u2013drug interactions, e.g., with anti-tuberculosis or anti-obesity medications.<\/jats:p>","DOI":"10.3389\/fmed.2025.1509074","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:22:49Z","timestamp":1740554569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region"],"prefix":"10.3389","volume":"12","author":[{"given":"Mohamed A.","family":"Yassin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Al Farsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Ghasoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayane","family":"Mheidly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Aal","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref1","volume-title":"Chronic lymphocytic leukemia","author":"Mukkamalla","year":"2024"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed Eng Online"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1182\/blood-2023-182574","article-title":"Patterns of disease, risk factors and treatment in chronic lymphocytic leukemia (CLL). A retrospective report of real world patient cohort from United Arab Emirates","volume":"142","author":"Alam","year":"2023","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.leukres.2021.106668","article-title":"Chronic lymphocytic leukemia in a young population","volume":"110","author":"Alshemmari","year":"2021","journal-title":"Leuk Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12885-024-12343-1","article-title":"Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort","volume":"24","author":"Alshemmari","year":"2024","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e29271","DOI":"10.1097\/MD.0000000000029271","article-title":"Hematological indices reference intervals for a healthy Arab population in Qatar: effect of age, gender, and geographic location","volume":"101","author":"Yassin","year":"2022","journal-title":"Medicine"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e30431","DOI":"10.1097\/MD.0000000000030431","article-title":"Prevalence of neutropenia among adult Arabs in Qatar: relation to other hematological parameters and anthropometric data","volume":"101","author":"Yassin","year":"2022","journal-title":"Medicine"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/cancers13102468","article-title":"Current treatment options in CLL","volume":"13","author":"Bewarder","year":"2021","journal-title":"Cancers"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11912-023-01482-6","article-title":"Chronic lymphocytic leukemia: time-limited therapy in the first-line setting and role of minimal residual disease","volume":"26","author":"Stumpf","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jha2.888","article-title":"A decade of chronic lymphocytic leukaemia therapy in Germany: real-world treatment patterns and outcomes (2010-2022)","volume":"5","author":"Wartmann","year":"2024","journal-title":"EJHaem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration Ibrutinib-Venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14737140.2023.2288899","article-title":"Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials","volume":"24","author":"Molica","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line Venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests Venetoclax (ABT-199) as optimal partner with Ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration Ibrutinib plus Venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1182\/blood.2022015963","article-title":"A CAPTIVATE-ing new regimen for CLL","volume":"139","author":"Rogers","year":"2022","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-22-0504","article-title":"Effective tumor Debulking with Ibrutinib before initiation of Venetoclax: results from the CAPTIVATE minimal residual disease and fixed-duration cohorts","volume":"28","author":"Barr","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration Ibrutinib plus Venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref28","volume-title":"NCCN clinical practice guidelines in oncology chronic lymphocytic leukemia\/small lymphocytic lymphoma version 1.2025","year":"2024"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"ref32","volume-title":"Prescribing information","year":"2022"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","volume":"2020","author":"Fischer","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 Venetoclax-treated CLL patients in routine clinical practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"OP2400417","DOI":"10.1200\/OP.24.00417","article-title":"Evaluation of the impact of monitoring for tumor lysis during Venetoclax ramp-up in chronic lymphocytic leukemia in routine clinical practice","volume":"22","author":"Ghosh","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3390\/cancers16112079","article-title":"The safety of novel therapies in chronic lymphocytic leukemia in the era of intermittent fasting: a pharmacology-based review","volume":"16","author":"Benkhadra","year":"2024","journal-title":"Cancers"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"Von Hundelshausen","year":"2021","journal-title":"Cancers"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.19082\/5740","article-title":"Profile of peptic ulcer disease and its risk factors in Arar","volume":"9","author":"Albaqawi","year":"2017","journal-title":"Northern Saudi Arabia Electr Physician"},{"key":"ref40","first-page":"813","article-title":"Effect of Ramadan fasting on intragastric pH recorded during 24 hours in healthy subjects","volume":"21","author":"Iraki","year":"1997","journal-title":"Gastroenterol Clin Biol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1177\/147323000903700637","article-title":"Does Ramadan fasting increase acute upper gastrointestinal haemorrhage?","volume":"37","author":"Ozkan","year":"2009","journal-title":"J Int Med Res"},{"key":"ref42","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J Res Med Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00277-024-05625-y","article-title":"Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis","volume":"103","author":"Murru","year":"2024","journal-title":"Ann Hematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4314\/ahs.v23i3.43","article-title":"Epidemiological features of tuberculosis in the Middle East and North Africa from 1990 to 2019: results from the global burden of disease study 2019","volume":"23","author":"Moradinazar","year":"2023","journal-title":"Afr Health Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/17474086.2021.1875818","article-title":"Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review","volume":"14","author":"Iqbal","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000528019","article-title":"Ibrutinib and Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular Tachyarrhythmias\/sudden cardiac death","volume":"68","author":"Boriani","year":"2023","journal-title":"Chemotherapy"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2023-174560","article-title":"Pre-existing cardiovascular disease increases the risk of cardiovascular adverse events during Bruton tyrosine kinase inhibitor therapy","volume":"142","author":"Fernandez Turizo","year":"2023","journal-title":"Blood"},{"key":"ref51","first-page":"1","article-title":"Diabetes in the Arab world","volume-title":"Handbook of healthcare in the Arab world","author":"Khan","year":"2021"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e062053","DOI":"10.1136\/bmjopen-2022-062053","article-title":"Prevalence and associated risk factors of overweight and obesity among adult population in Dubai: a population-based cross-sectional survey in Dubai, the United Arab Emirates","volume":"13","author":"Mamdouh","year":"2023","journal-title":"BMJ Open"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_32_18","article-title":"Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates","volume":"20","author":"Al Mahmeed","year":"2019","journal-title":"Heart Views"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1186\/s12889-020-08678-6","article-title":"The cascade of care in managing hypertension in the Arab world: a systematic assessment of the evidence on awareness, treatment and control","volume":"20","author":"Akl","year":"2020","journal-title":"BMC Public Health"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1200\/JCO.2023.41.16_suppl.7537","article-title":"Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)","volume":"41","author":"Rogers","year":"2023","journal-title":"JCO"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/blood-2023-187743","article-title":"Comparative effectiveness of Ibrutinib flexible dosing treatment strategies on time to next treatment in a largely community-based claims database: a target trial emulation study","volume":"142","author":"Ghosh","year":"2023","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1182\/blood-2023-181774","article-title":"Impact of Ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1200\/JCO.2023.41.16_suppl.7538","article-title":"Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials","volume":"41","author":"Stephens","year":"2023","journal-title":"JCO"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e24922b0","DOI":"10.1097\/01.HS9.0000969388.24922.b0","article-title":"P 621: real-world dosing patterns and time to next treatment for previously untreated patients with Cll\/Sll with or without Ibrutinib dose reduction following an adverse event","volume":"7","author":"Shadman","year":"2023","journal-title":"Hema Sphere"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"8074837","DOI":"10.1155\/2022\/8074837","article-title":"Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: a systematic review and Meta-analysis","volume":"2022","author":"Okati-Aliabad","year":"2022","journal-title":"J Obes"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/IJNRD.S363133","article-title":"Chronic kidney disease Management in the Middle East and Africa: concerns, challenges, and novel approaches","volume":"16","author":"Al-Ghamdi","year":"2023","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref62","volume-title":"Prescribing information","year":"2023"},{"key":"ref63","volume-title":"Prescribing information","year":"2022"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardio oncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC Cardio Oncol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1573406416666200611104143","article-title":"The burden of cardiovascular disease risk factors in the Middle East: a systematic review and Meta-analysis focusing on primary prevention","volume":"19","author":"Bhagavathula","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"444","DOI":"10.5220\/0012373700003657","article-title":"Unpacking the clinical burden of leukemia in GCC: Implications for patient care","volume":"2","author":"Aboelkhir","year":"2024","journal-title":"Scitepress"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1112616","DOI":"10.3389\/fonc.2023.1112616","article-title":"Measurable residual disease in chronic lymphocytic leukemia","volume":"13","author":"Benintende","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1509074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:22:54Z","timestamp":1740554574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1509074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":67,"alternative-id":["10.3389\/fmed.2025.1509074"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1509074","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1509074"}}